Core Viewpoint - Multiple myeloma, the second most common hematological malignancy, poses significant treatment challenges due to its incurable nature and high relapse rates, but advancements in medical technology have led to innovative therapies that offer hope for "functional cure" and improved quality of life for patients [1][8]. Group 1: Disease Overview - Multiple myeloma is characterized by malignant proliferation of plasma cells, which are crucial for immune function, leading to the production of ineffective immunoglobulins that harm normal bodily functions [3][4]. - The disease's early symptoms are often non-specific, leading to misdiagnosis, with common symptoms summarized by the "CRAB" acronym: hypercalcemia, renal impairment, anemia, and bone lesions [3][4]. Group 2: Diagnosis and Monitoring - Patients often seek treatment for symptoms like renal issues or bone pain, mistakenly attributing them to other conditions, which can delay diagnosis and worsen outcomes [4][5]. - Monitoring serum protein levels is critical, with levels exceeding 50 g/L warranting further investigation for multiple myeloma [4]. Group 3: Treatment Approaches - Treatment for multiple myeloma is individualized, with options including traditional chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation, depending on patient-specific factors [7][9]. - Recent advancements have introduced bispecific antibodies as a standard treatment for relapsed/refractory multiple myeloma, showing efficacy rates over 60% and complete response rates around 35% [9]. Group 4: Prognosis and Future Directions - The five-year survival rate for multiple myeloma patients has improved significantly, with many now living for over a decade, thanks to new therapies [8][9]. - The concept of "functional cure" is emerging, where patients may have residual tumor cells that are undetectable and coexist with the immune system, allowing for a normal quality of life [9].

Group 1 - The stock price of Shuyou Shen closed at 48.76 yuan on August 6, 2025, down by 1.32 yuan, a decline of 2.64% from the previous trading day [1] - The stock reached a high of 52.37 yuan and a low of 47.60 yuan during the day, with a volatility of 9.52% [1] - The trading volume was 213,300 hands, with a total transaction value of 1.063 billion yuan, resulting in a turnover rate of 4.52% [1] Group 2 - Shuyou Shen operates in the biopharmaceutical industry, focusing on the research and production of innovative drugs, primarily monoclonal antibodies [1] - The company is headquartered in Beijing and is listed on the ChiNext board [1] Group 3 - On the morning of August 6, the stock price of Shuyou Shen experienced a rapid decline of over 2% within 5 minutes [1] - The net outflow of main funds on August 6 was 34.21 million yuan, with a cumulative net outflow of 412 million yuan over the past five days [1]